Some patients benefit from cycling: taking semaglutide intensively for 36 months, tapering, maintaining weight independently for several months, then restarting if cravings return
Posting a purchase link alongside a protocol guide, with no medical history intake, is not responsible health content regardless of how well the compound works in a controlled trial
April 2023 | Volume 22 | Issue 4 | 413 | Copyright April 2023 Published online March 14, 2023 doi:10.36849/JDD.6550 Citation: Ouellette S, Frias G, Shah R, et al
Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) demonstrated significant reductions in major adverse cardiovascular events, while others showed cardiovascular safety without superiority
Differences between GLP-1R agonists GLP-1R agonists already in the market and others in development present the same mode of action and, having the same pleiotropic effects of native GLP-1, the differences in clinical profiles between them are related to differences in pharmacokinetics, structure and size of each formulation
